Deepak Singhal
Overview
Explore the profile of Deepak Singhal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
312
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Neller M, Ambalathingal G, Hamad N, Sasadeusz J, Pearson R, Holmes-Liew C, et al.
Nat Commun
. 2024 Dec;
15(1):10339.
PMID: 39627190
Adoptive T-cell immunotherapy holds great promise for the treatment of viral complications in immunocompromised patients resistant to standard anti-viral strategies. We present a retrospective analysis of 78 patients from 19...
2.
Singhal D, Kutyna M, Hahn C, Shah M, Hiwase D
Blood Cancer Discov
. 2024 Oct;
5(6):400-416.
PMID: 39422544
Therapy-related myeloid neoplasm (t-MN), characterized by its association with prior exposure to cytotoxic therapy, remains poorly understood and is a major impediment to long-term survival even in the era of...
3.
Thangudu R, Holck M, Singhal D, Pilozzi A, Edwards N, Rudnick P, et al.
Cancer Res Commun
. 2024 Sep;
4(9):2480-2488.
PMID: 39225545
Significance: The Proteomic Data Commons (PDC) plays a crucial role in advancing cancer research by providing a centralized repository of high-quality cancer proteomic data, enriched with extensive clinical annotations. By...
4.
Nerurkar N, Goyal S, Singhal D
J Voice
. 2024 May;
PMID: 38705739
Objectives: Though hemorrhagic vocal fold polyps are a common entity, hemorrhagic vocal fold cysts have not been previously described. In our study, we have evaluated patients who were diagnosed on...
5.
Sharplin K, Proudman W, Chhetri R, Tran E, Choong J, Kutyna M, et al.
Cancers (Basel)
. 2023 Aug;
15(16).
PMID: 37627047
Azacitidine is an approved therapy for higher-risk myelodysplastic syndrome (MDS). However, only 30-40% patients respond to azacitidine, and the responses may take up to six cycles to become evident. Delayed...
6.
Li Y, Dou Y, Veiga Leprevost F, Geffen Y, Calinawan A, Aguet F, et al.
Cancer Cell
. 2023 Aug;
41(8):1397-1406.
PMID: 37582339
The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC) investigates tumors from a proteogenomic perspective, creating rich multi-omics datasets connecting genomic aberrations to cancer phenotypes. To facilitate pan-cancer investigations,...
7.
Homan C, Drazer M, Yu K, Lawrence D, Feng J, Arriola-Martinez L, et al.
Blood Adv
. 2023 Jul;
7(20):6092-6107.
PMID: 37406166
Individuals with germ line variants associated with hereditary hematopoietic malignancies (HHMs) have a highly variable risk for leukemogenesis. Gaps in our understanding of premalignant states in HHMs have hampered efforts...
8.
Shah M, Tran E, Shah S, Chhetri R, Baranwal A, Ladon D, et al.
Blood Cancer J
. 2023 Apr;
13(1):51.
PMID: 37041128
Revised diagnostic criteria for myeloid neoplasms (MN) issued by the International Consensus Classification (ICC) and the World Health Organization (WHO) recommended major change pertaining to TP53-mutated (TP53) MN. However, these...
9.
Baranwal A, Chhetri R, Yeung D, Clark M, Shah S, Litzow M, et al.
Bone Marrow Transplant
. 2023 Apr;
58(7):769-776.
PMID: 37012415
Therapy-related myeloid neoplasms (t-MN) are aggressive myeloid neoplasms. Factors predicting post-allogeneic stem cell transplant (alloSCT) survival are not well-known. We studied the prognostic utility of factors at: t-MN diagnosis, pre-alloSCT,...
10.
Montarello N, Leslie A, Chhetri R, Friel O, Singhal D, Ross D, et al.
Blood Adv
. 2023 Mar;
7(13):3032-3035.
PMID: 36884290
No abstract available.